{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:38:45Z","timestamp":1793709525735,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.07.033","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:12:38Z","timestamp":1785539558000},"page":"1933-1945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4343-045X","authenticated-orcid":false,"given":"David","family":"Le\u00f3n-Jim\u00e9nez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-2034","authenticated-orcid":false,"given":"Sergio","family":"Mart\u00ednez-Herv\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagore","family":"Lois-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-4027","authenticated-orcid":false,"given":"Carlos","family":"Jeric\u00f3-Alba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Mart\u00ednez-Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Royuela-Juncadella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1061-0200","authenticated-orcid":false,"given":"Anabel","family":"Franco-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rodr\u00edguez-Carnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4764-9440","authenticated-orcid":false,"given":"Jos\u00e9 F.","family":"Varona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-5975","authenticated-orcid":false,"given":"Alberto","family":"Muela-Molinero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8122-1269","authenticated-orcid":false,"given":"Roc\u00edo","family":"Garc\u00eda-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Castiella-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cainzos-Achirica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0882-1247","authenticated-orcid":false,"given":"Anal\u00eda","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Guti\u00e9rrez-Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2247-9679","authenticated-orcid":false,"given":"Jos\u00e9 Pablo","family":"Miramontes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Luque-Linero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9741-2471","authenticated-orcid":false,"given":"Miguel \u00c1ngel","family":"V\u00e1zquez-Ronda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1923-4272","authenticated-orcid":false,"given":"Ana","family":"Torres-Do-Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-1308","authenticated-orcid":false,"given":"Pablo","family":"Gonz\u00e1lez-Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-2627","authenticated-orcid":false,"given":"Carlos","family":"Puig-Jov\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.07.033_bib1","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib3","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.033_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1177\/2047487320908698","article-title":"Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE v survey in 16 European countries","volume":"28","author":"Kotseva","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.07.033_bib6","first-page":"e1154","article-title":"ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"153","author":"Members","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.07.033_bib7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.033_bib8","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib9","first-page":"257","article-title":"Bempedoic acid (ETC-1002)","volume":"36","author":"Saeed","year":"2018","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.jacl.2026.07.033_bib10","first-page":"53","article-title":"Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties. Clinica e Investigacion En","volume":"33","author":"Masana Mar\u00edn","year":"2021","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jacl.2026.07.033_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.033_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.033_bib13","first-page":"8","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.07.033_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.033_bib15","first-page":"117","article-title":"Effect of bempedoic acid on atherogenic lipids and inflammation: a meta-analysis","volume":"33","author":"Masson","year":"2021","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.jacl.2026.07.033_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.07.033_bib17","first-page":"310","article-title":"Uso de nuevas terapias hipolipemiantes en la pr\u00e1ctica cl\u00ednica. Consenso SEC\/SEA\/SEEN\/SEMFYC\/SEMERGEN\/SEMG\/SEN\/SEACV\/S.E.N","volume":"59","author":"Vivas","year":"2024","journal-title":"REC: CardioClinics"},{"key":"10.1016\/j.jacl.2026.07.033_bib18","first-page":"113","article-title":"Real world evidence of bempedoic acid on efficacy and safety in patients with uncontrolled LDL-c and at high risk of CVD","volume":"12","author":"Manoj","year":"2023","journal-title":"Cardiol\u00a0Angiol: Int\u00a0J"},{"key":"10.1016\/j.jacl.2026.07.033_bib19","first-page":"13","article-title":"A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets","author":"Ramachandran","year":"2024","journal-title":"Drugs Context"},{"key":"10.1016\/j.jacl.2026.07.033_bib20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/03007995.2024.2341870","article-title":"Lipid clinic experience with bempedoic acid in three UK centres","volume":"40","author":"Jakubowska","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2026.07.033_bib21","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.atherosclerosis.2023.06.840","article-title":"Real-life experience of the first patients treated with bempedoic acid in 2 lipid clinics of Belgium","volume":"379","author":"Demeure","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.07.033_bib22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/jcm14061839","article-title":"Clinical utilization and performance of bempedoic acid in an Italian real-world setting: insight from Campania region","volume":"14","author":"Russo","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacl.2026.07.033_bib23","unstructured":"MILOS study: The real-world use of bempedoic acid n.d. https:\/\/www.clinicaltrialsarena.com\/analyst-comment\/milos-study-bempedoic-acid\/ (accessed December 27, 2024)."},{"key":"10.1016\/j.jacl.2026.07.033_bib24","first-page":"3912","article-title":"ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society","volume":"45","author":"McCarthy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib25","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142026","volume":"49","author":"Diabetes* ADAPPC for","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2026.07.033_bib26","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.07.033_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.athplu.2026.01.007","article-title":"LDL-C lowering in patients treated with bempedoic acid in a real-world cohort","volume":"63","author":"Nelson","year":"2026","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.jacl.2026.07.033_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvab064","article-title":"Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose\u2013response model","volume":"8","author":"Jadhav","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacl.2026.07.033_bib29","unstructured":"Food and DrugAdministration. Nexletol (bempedoic acid) tablets, for oral use. prescribing information. 2020 (updated 2026). n.d. https:\/\/www.accessdata.fda.gov (accessed April 19, 2026)."},{"key":"10.1016\/j.jacl.2026.07.033_bib30","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.07.033_bib31","first-page":"19","article-title":"Clinical implementation of bempedoic acid in blood lipid management: real-world data from an Italian lipid clinic","author":"Pavanello","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.07.033_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:18:37Z","timestamp":1793708317000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1933287426004599"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.033","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, safety, and treatment persistence of bempedoic acid in a Spanish real-world cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.07.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}